You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Regimen
Intent: Adjuvant
Oct 2017
Regimen
Intent: Adjuvant
Oct 2017
Regimen
Intent: Adjuvant
Oct 2017
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    crizotinib - First or second-line treatment for ALK-positive advanced NSCLC, according to specific criteria
Exceptional Access Program
    crizotinib - First-line treatment for ROS1-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC, according to specific criteria
Mar 2021
Regimen
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative
Funding:
ODB - General Benefit
  • prednisone
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit
    prednisone
Oct 2017
Regimen
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Neoadjuvant, Palliative
Oct 2017
Regimen
Cancer Type:
Skin, 
Merkel Cell
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant
Mar 2021

Pages